Recombinant Human EZH2 Protein

Name: Recombinant Human EZH2 Protein
Brand: Beta LifeScience
SKU: BL-1416SG
Availability: InStock

Collections: High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	GST
Host Species	Human
Accession	BC010858
Synonym	ENX-1, EZH1, MGC9169
Background	EZH2 (enhancer of zeste homolog 2) belongs to the polycomb group (PcG) protein and acts as the catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of target genes. EZH2 expression is associated with proliferating tissues and shares an overlapping set of target genes with EZH1. Compared to PRC2-EZH1, PRC2-EZH2 exhibits higher levels of histone methyltransferase (HKMT) activity.
Description	Recombinant full-length human EZH2 was produced by baculovirus in Sf9 insect cells, fused with a GST tag at N-terminus. This protein is purified with our unique purification methods.
Source	Sf9 insect cells
AA Sequence	Full Length
Molecular Weight	~130 kDa
Purity	For specific purity information on a given lot, see related COA.
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Formulation	Recombinant protein is supplied in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM Glutathione, 0.25mM DTT, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.
Stability	The recombinant protein is stable for up to 12 months at -70°C
Usage	For Research Use Only
Storage	Recombinant Human EZH2 Protein should be stored should be stored at < -70°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function	Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.
Subcellular Location	Nucleus.
Protein Families	Class V-like SAM-binding methyltransferase superfamily, Histone-lysine methyltransferase family, EZ subfamily
Database References	HGNC: 3527 OMIM: 277590 KEGG: hsa:2146 STRING: 9606.ENSP00000320147 UniGene: PMID: 30071900 Mechanistic studies in human breast cancer cell lines revealed that miR-92b directly targeted EZH2 promoting autophagy, and inhibiting the viability and invasion of breast cancer cells. PMID: 30066891 HOXD-AS1 could interact with EZH2, and then repress p57 expression, to aggravate osteosarcoma oncogenesis. PMID: 30119259 p38-mediated phosphorylation at threonine 367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. PMID: 30022044 Study suggests the higher expressions of HOTAIR and EZH2 among three breast cancer cell lines. HOTAIR could bind specifically to EZH2 and PTEN, highlighting the capability of HOTAIR to inhibit the expression of PTEN by recruiting EZH2 in breast cancer. Downregulation of HOTAIR or silencing of EZH2 was noted to inhibit the proliferation, invasion, and migration of breast cancer cells, while promoting their apoptosis. PMID: 30048163 Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program driven by FOXC1. PMID: 29959321 Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors PMID: 29438697 The EZH2 expression is decreased in multiple sclerosis patients PMID: 30367633 EZH2 regulates the expression of miR-139-5p via H3K27me3, and the EZH2/miR-139-5p axis participates in the progression of Pancreatic cancer. PMID: 30304920 data demonstrated that in brain glioma cells, the decrease of EZH2 level could suppress cell proliferation and tumorigenesis potency, and meanwhile inhibit the expressions of oncogenes including c-myc and Akt. PMID: 30305602 In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac). PMID: 29371630 FOXP4-AS1 is overexpressed in osteosarcoma (OS), and is the independent risk factor in OS prognosis. Upregulated FOXP4-AS1 promotes the proliferation, migration and cell cycle, but inhibits apoptosis of OS cells. Furthermore, FOXP4-AS1 participates in the development and progression of OS by downregulating LATS1 via binding to LSD1 and EZH2. PMID: 29859193 High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with prostate cancer, at diagnosis. PMID: 29174711 High EZH2 expression is associated with high-grade upper tract urothelial carcinoma. PMID: 29748098 Enhancer of Zeste Homolog 2 (EZH2), SET domain, bifurcated 1 protein (SETDB1), lysine-specific histone demethylase 1 (LSD1), histone H3 methylation (H3K9me3 and H3K27me3) expression are altered in colorectal cancer (CRC) and may play a role in colorectal carcinogenesis. PMID: 30105513 Data show that miR-1301 inhibited the expression of enhancer of zeste homolog 2 protein (EZH2) by binding to the 3' untranslated regions (3'-UTR) of EZH2 gene. PMID: 29790898 We characterized a lncRNA, PCa specific expression and EZH2-associated transcript (PCSEAT, annotated as PRCAT38), which is specifically overexpressed in prostate cancer. PCSEAT promotes cell proliferation, at least in part by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2. PMID: 29803673 Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells. PMID: 29185157 these data indicate that RING1B and EZH2 repress the innate inflammatory cutaneous squamous cell carcinoma function and impair tumor immunosurveillance PMID: 29394319 The interaction of methyltransferase EZH2 or demethylase JMJD3 on RGMA, RARb2, AR, PGR, and ERa genes in the progression and aggressiveness of prostate cancer. PMID: 29161520 Results show that EZH2 expression was significantly higher in lung adenocarcinoma (LA) and that EZH2 promotes LA cell invasion and metastasis by inhibiting SPRY4-IT1 expression. PMID: 28796375 Study identifies the residues on EZH2 that are critical for its interaction with VAV and demonstrate that EZH2 interactions with VAV proteins are crucial for the regulation of adhesion dynamics and cellular transformation. PMID: 28967906 Study shows that EZH2 contributes to PARP inhibitors sensitivity in breast cancer cells. Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2. PMID: 28925391 Primary cutaneous follicle center lymphomas with concomitant 1p36 deletion and TNFRSF14 mutations frequently express high levels of EZH2 protein. PMID: 29858685 Curcumol inhibits proliferation and induces apoptosis by targeting EZH2. PMID: 29852354 EZH2, ET-1, and CD34 may act as biomarkers of aggressive cervical squamous cell carcinoma PMID: 29630085 the hsa_circ_0071589/miR-600/EZH2 axis may play critical regulatory roles in the pathogenesis of colorectal cancer. PMID: 29710537 EZH2 mutations coexisted with mutations of NOTCH1, IL7R, and PHF6 in the two Adult T-cell Acute Lymphoblastic Leukemia patients, and they responded poorly to chemotherapy and experienced difficult clinical histories and inferior outcomes PMID: 28747286 An explicit oncogenic role of TP73-AS1 in the NSCLC tumorigenesis, suggesting a TP73-AS1-miR-449a-EZH2 axis and providing new insight for NSCLC tumorigenesis. PMID: 29803931 results show the effect of individual O-GlcNAcylation sites on the function of EZH2 and suggest an alternative approach to tumor suppression through selective inhibition of EZH2 O-GlcNAcylation. PMID: 29941599 High EZH2 expression is associated with gastric cancer. PMID: 30031062 combined panel had the highest sensitivity and specificity at 96.3% and 100%, which was significantly or marginally higher than those of EZH2, C-KIT, and CD205 alone PMID: 29487009 EZH2 positivity was significantly correlated with WHO tumor grade and worse prognosis in gliomas. PMID: 28862715 Long non-coding RNA H19 was found to play an oncogenic role in oral squamous cell carcinoma cells by regulating EZH2 and by targeting miR138. PMID: 29344674 In univariable analysis, patients carrying mutations in DNMT3A, U2AF1, and EZH2 had worse overall and relapse-free survival. PMID: 29321554 EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. PMID: 29358618 The results indicated that when STAT3 signaling activity was attenuated by Stattic or enhanced with a STAT3 plasmid, the EZH2/miR-200 axis was markedly altered, thus resulting in modulation of the invasion and migration of OSCC cell lines. PMID: 29532870 Data suggest the polycomb repressive complex 2 subunits EZH2, SUZ12, and EED protein axis as promising therapeutic target for treating sarcoma. PMID: 29415665 Results demonstrate that EZH2 inhibition enhances HCC eradication by NK cells and that EZH2 functions, in part, as an oncogene by inhibiting immune response. PMID: 29581297 Heat-treated human dermal fibroblast exhibited a reduction in lncRNA LET expression and increase in EZH2 expression. PMID: 29393360 EZH2 rs12670401 and rs6464926 polymorphisms, EZH2 and SMYD3 expression, clinical staging, lymph node metastasis, human epidermal growth factor receptor-2 (HER2) status, and metastasis may be correlated with breast cancer susceptibility and prognosis. PMID: 29089464 These data inferred that long non-coding RNA PVT1 could be served as an indicator of glioma prognosis, and PVT1-EZH2 regulatory pathway may be a novel therapeutic target for treating glioma. PMID: 29046366 Enhancer of zeste homolog 2 (EZH2) overexpression is associated with malignant potential in thyroid cancer, and may thus be a useful prognostic marker of aggressive thyroid cancer. PMID: 29275295 EZH2 increases STAT3 phosphorylation and upregulates the expression of 72 kDa type IV collagenase and overexpression of EZH2 was demonstrated to increase the proliferation and invasive potential of renal cell carcinoma cells. PMID: 29286132 High glucose enhances the formation of EZH2/Snail/HDAC1 complex in the nucleus, which in turn causes E-cadherin repression. PMID: 29705809 Patients with all of the following: the tumor size PMID: 28738014 Upregulation of circRNA BCRC4 promoted apoptosis and inhibited viability of bladder cancer cells, up-regulated BCRC4-increased miR-101 level, which suppressed EZH2 expression in both RNA and protein levels. PMID: 29270748 Our data demonstrates that EZH2 participates in Glioblastoma multiforme-induced immune deficient and EZH2 suppression in Glioblastoma multiforme can remodel microglia immune functions PMID: 29132376 Coexistence of BRAF V600E mutation and EZH2 gain is rather prevalent in melanoma. PMID: 29202777 MiR-4465 suppressed cancer cells proliferation and metastasis by directly targeting the oncogene EZH2. PMID: 29169732

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.